Q1 2025 Coherus BioSciences Inc Earnings Call Transcript

May 12, 2025 / 09:00 PM GMT

Release Date Price: $1.02 (+5.30%)

Transcript 10-Q8-K

Key Points

Positve

Coherus BioSciences Inc (CHRS) has transitioned into a commercial stage innovative oncology company with an FDA-approved PD1 inhibitor, torapalamab, which is the standard of care for nasopharyngeal carcinoma.
The company projects significant revenue growth from torapalamab, expecting it to generate $150 to $200 million annually over the next three years.
Coherus BioSciences Inc (CHRS) has a robust pipeline with promising candidates like CHS-114 and Casozo keto, targeting large market opportunities in oncology.
The company has implemented strategic partnerships to expand indications for its products, reducing development costs and enhancing market potential.
Coherus BioSciences Inc (CHRS) has achieved significant cost savings from headcount reductions and divestitures, improving financial efficiency.

Negative

The company experienced a transitional quarter with flat revenue growth due to a seasonal inventory drawdown despite increased patient demand.
There were disruptions in sales momentum due to the divestiture and restructuring of the sales force, impacting short-term growth.
Coherus BioSciences Inc (CHRS) faces challenges in increasing awareness and adoption of its products among physicians, particularly in the community setting.
The company is navigating a competitive landscape with other PD1 inhibitors and needs to differentiate its offerings effectively.
There are uncertainties related to regulatory changes and FDA staffing, which could impact future approvals and market strategies.

Refinitiv StreetEvents Event Transcript
E D I T E D V E R S I O N

CHRS.OQ - Coherus BioSciences Inc
Q1 2025 Coherus BioSciences Inc Earnings Call
May 12, 2025 / 09:00PM GMT

=====================
Presentation
--------------------------------------------------------------------------------
Unidentified_1 [1]
--------------------------------------------------------------------------------
Good day and thank you for standing by. Welcome to the coherence Biosciences first quarter 2025 earnings conference call. At this time, all participants are in a listen-only mode. After the speaker's presentation, there will be a question and answer session. To ask a question during the session, you will need to press 11 on your telephone. You will then hear an automated message advising your hand is raised to withdraw your question, please press 11 again. Please be advised that today's conference is being recorded.

I would now like to hand a conference over to your speaker today, Jody Seevers, head of investor relations. Please go ahead.

-------------------------------------------------------------------------

Already have an account? Log in

Get the full story

Subscribe Now

	Access to All Earning Calls and Stock Analysis
	30-Year Financial on one screen
	All-in-one Stock Screener with unlimited filters
	Customizable Stock Dashboard
	Real Time Insider Trading Transactions
	8,000+ Institutional investors’ 13F holdings
	Powerful Excel Add-in and Google sheets Add-on
	All data downloadable
	Quick customer support
	And much more...

7-Day Free Trial · Cancel Anytime

Subscription fee may be tax deductible.

Excellent

4.6 out of 5

Trustpilot

Research Tools

All-In-One Screener Stock Ideas Stock List Guru List Guru Real-Time Picks Insider List Insider Trades Economic Indicators Sector & Industry Performance DCF Calculator Calculators Discussion Board

Product

Pricing Plans Excel Add-In Google Sheets Add-on Data API Stock Comparison Table Manual of Stocks Instant Alerts Mobile App Newsletters Signup 中文

Education

Financial Glossary Tutorials FAQ Buffett Indicator Shiller P/E Yield Curve Today U.S. Inflation Rate Global Market Valuation Fed Net Liquidity Buffett Assets Allocation

Company

About GuruFocus Career Contact Us Advertise Term of Use Privacy Policy Referral Program Partner Program

Survey

We'd love to learn more about your experiences on GuruFocus.com and how we can improve!

Take Survey

Disclaimers

GuruFocus.com is not operated by a broker or a dealer. Under no circumstances does any information posted on GuruFocus.com represent a recommendation to buy or sell a security. The information on this site, and in its related newsletters, is not intended to be, nor does it constitute investment advice or recommendations. The individuals or entities selected as "gurus" may buy and sell securities before and after any particular article and report and information herein is published, with respect to the securities discussed in any article and report posted herein. Gurus may be added or dropped from the GuruFocus site at any time. In no event shall GuruFocus.com be liable to any member, guest or third party for any damages of any kind arising out of the use of any content or other material published or available on GuruFocus.com, or relating to the use of, or inability to use, GuruFocus.com or any content, including, without limitation, any investment losses, lost profits, lost opportunity, special, incidental, indirect, consequential or punitive damages. Past performance is a poor indicator of future performance. The information on this site, and in its related newsletters, is not intended to be, nor does it constitute investment advice or recommendations. The information on this site is in no way guaranteed for completeness, accuracy or in any other way. The gurus listed in this website are not affiliated with GuruFocus.com, LLC. Stock quotes are provided by QuoteMedia, Inc. (CSI). Company fundamental data is provided by Morningstar. Analyst estimates data is sourced from both Refinitiv and Morningstar, with priority given to Refinitiv data. Data is updated daily.